The EVERY Company, the leading precision fermentation platform accelerating a global transition to animal-free protein, today announced it has closed $175 million in Series C financing. The round was co-led by new investor, McWin, and existing investor, Rage Capital. Other new and existing investors joined the round including Temasek, Grosvenor's Wheatsheaf Group, and TO Ventures. Prosus Ventures also contributed to the funding, marking its first investment in synthetic biology.

The EVERY Company is the market leader in engineering, manufacturing and formulating animal-free animal proteins for the global food and beverage industry. Leveraging precision fermentation to produce hyper-functional and one-to-one replacement proteins from microorganisms, EVERY™ is on a mission to decouple the world's proteins from the animals that make them. Originally founded as Clara Foods in 2014, EVERY™ rebranded in 2021 to better convey its vision to bring animal-free proteins to everyone, everywhere.